Related Experiment Video
Updated: Jan 30, 2026

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Graft Versus Host Disease Clinical Trials: Is it Time for Patients Centered Outcomes to Be the Primary Objective?
1CIBMTR (Center for International Blood and Marrow Transplant Research)/Froedtert, Department of Medicine, Medical College of Wisconsin, 9200 W. Wisconsin Ave., Suite C5500, Milwaukee, WI, 53226, USA. beshaw@mcw.edu.
Purpose Of Review:
Graft versus host disease (GVHD) is a common complication following hematopoietic cell transplant and is associated with a high symptom burden, reduced functional status, and impaired quality of life (QOL). QOL is best assessed by patient-reported outcomes (PRO). Numerous clinical trials for the prevention and treatment of GVHD are available. This review aims to understand the landscape of PRO inclusion in clinical trials for GVHD over the last decade.
Recent Findings:
Consensus bodies, including experts in GVHD, PRO, and clinical trials have made recommendations for a standardized approach for the inclusion of PRO in clinical trials including as primary outcomes, however, these have yet to be implemented in a consistent manner in practice. Consistently applying consensus recommendation in chronic GVHD will ensure that PROs are appropriately included in clinical trials. Development of validated measures in acute GVHD and composite outcomes for all GVHD trials are required.
More Related Videos
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Patient-centered Care
Statistical Software for Data Analysis and Clinical Trials
Chronic Kidney Disease II: Clinical Manifestations
Coronary Artery Disease III: Clinical Manifestations

